OTL Announcements
Announcements
-
Metabolize Licenses Two Proprietary Metabolites to Address Obesity from Stanford OTL
The licensing agreement is for two promising metabolites with the potential to significantly improve metabolic health and naturally address the obesity epidemic.
July 30, 2024
-
Clearing the path to commercialization
Stanford’s High Impact Technology (HIT) Fund is kicking off its third year of helping researchers commercialize their most promising ideas.
June 18, 2024
-
Stanford Startup Mozart Therapeutics Doses First Cohort of Participants in Phase 1a/b Clinical Study of MTX-101, in Development for Treatment of Autoimmune Diseases
Study to Evaluate MTX-101 for Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Adults and Patients
June 17, 2024
-
SPOTLIGHT May 2024 - Annual Report FY2023
This edition brings you our FY2023 Annual Report: "Lab to Life: Advancing Innovation"
May 30, 2024
-
Stanford Startup Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion
SYNCAR-001 + STK-009 combination will be studied in two distinct lupus patient populations: non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN)
March 26, 2024
-
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
BridgeBio merged with Stanford Startup Eidos Therapeutics in 2021
March 04, 2024
-
Stanford Startup Synthekine Announces Strategic Collaboration with Sanofi
They've entered into worldwide collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases.
January 29, 2024
-
Stanford launches fund to bring campus innovations to industry
The High Impact Technology (HIT) Fund provides business guidance and industry connections to Stanford researchers and entrepreneurs, as well as awards of up to $250,000.
June 13, 2023
-
March 01, 2023
-
Stanford University and The Invus Group collaborate to develop glioblastoma drugs
The collaboration will enable the development of medications to treat a type of brain cancer.
January 09, 2023
-
Deerfield and Stanford University Create the Porter Alliance for Innovative Medicines
Deerfield Management Commits up to $130 Million to Support Stanford’s Innovative Translational Research
January 18, 2022
-
Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories
Through Stanford’s Innovative Medicines Accelerator (IMA), its researchers will be able to access Twist’s “Library of Libraries.”
April 07, 2021
-
Top US, UK, and EU Universities Working Together to Help Economies Fuel Post-COVID Recovery
Ten leading US, UK, & EU universities discuss with govt. leaders and funding bodies how to harness the enormous potential of research and commercialization for COVID-19 recovery.
September 18, 2020
-
Ensuring Access to Lifesaving Technologies During the Pandemic
Stanford, Harvard, and MIT commit to COVID-19 technology licensing principles, maximizing access to university innovations
April 07, 2020
